Literature DB >> 22867696

Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation.

Benoît Ho-Tin-Noé1, Jean-Baptiste Michel.   

Abstract

Neovascularization of atherosclerotic lesions favors their progression toward rupture. Despite this pathophysiological importance, data regarding the mechanism(s) initiating plaque neovascularization are scarce. Recent findings indicate that smooth muscle cells located underneath early aortic atheromatous lesions display a pro-angiogenic phenotype, and that lipid mediators derived from these lesions are potent inducers of this phenotypic change. Here, we discuss these new data suggesting that smooth muscle cells could be the central organizers of an angiogenic response initiated by the very first cause of the atheromatous disease, the accumulation and retention of lipids in the arterial wall.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22867696     DOI: 10.1016/j.tcm.2012.05.007

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  14 in total

Review 1.  From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta.

Authors:  Jean-Baptiste Michel; Guillaume Jondeau; Dianna M Milewicz
Journal:  Cardiovasc Res       Date:  2018-03-15       Impact factor: 10.787

2.  Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.

Authors:  Min Qi; Xiaoyuan Huang; Lei Zhou; Jianglin Zhang
Journal:  DNA Cell Biol       Date:  2014-04       Impact factor: 3.311

Review 3.  Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis.

Authors:  Longhou Fang; Chao Liu; Yury I Miller
Journal:  Transl Res       Date:  2013-10-02       Impact factor: 7.012

Review 4.  Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.

Authors:  Amy McCurley; Adam McGraw; Dafina Pruthi; Iris Z Jaffe
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

5.  Production of IL-8, VEGF and Elastase by Circulating and Intraplaque Neutrophils in Patients with Carotid Atherosclerosis.

Authors:  Franca Marino; Matteo Tozzi; Laura Schembri; Stefania Ferraro; Antonino Tarallo; Angela Scanzano; Massimiliano Legnaro; Patrizio Castelli; Marco Cosentino
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

6.  Relationship between enhanced intensity of contrast enhanced ultrasound and microvessel density of aortic atherosclerostic plaque in rabbit model.

Authors:  Xiangdong You; Pintong Huang; Chao Zhang; Minghui Wang; Ying Zhang; Yurong Hong; Shumei Wei; Chunmei Liu; Zhaoxia Pu; Jianmin Zhang; Shuyuan Chen
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

7.  Polymer-free dual drug-eluting stents evaluated in a porcine model.

Authors:  Bin Zhang; Bo Zheng; Xingang Wang; Qiuping Shi; Jia Jia; Yong Huo; Chunshui Pan; Jingyan Han; Ming Chen
Journal:  BMC Cardiovasc Disord       Date:  2017-08-15       Impact factor: 2.298

8.  Inhibition of LOXL1-AS1 alleviates oxidative low-density lipoprotein induced angiogenesis via downregulation of miR-590-5p mediated KLF6/VEGF signaling pathway.

Authors:  Xuan Cheng; Zhiwei Liu; Haifeng Zhang; Yajun Lian
Journal:  Cell Cycle       Date:  2021-07-31       Impact factor: 5.173

9.  Deciphering the stromal and hematopoietic cell network of the adventitia from non-aneurysmal and aneurysmal human aorta.

Authors:  Charles-Antoine Dutertre; Marc Clement; Marion Morvan; Knut Schäkel; Yves Castier; Jean-Marc Alsac; Jean-Baptiste Michel; Antonino Nicoletti
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  MiR-590-5p Inhibits Oxidized- LDL Induced Angiogenesis by Targeting LOX-1.

Authors:  Yao Dai; Zhigao Zhang; Yongxiang Cao; Jawahar L Mehta; Jun Li
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.